Stockwinners Market Radar for January 06, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:11 EST Cathie Wood's ARK Investment bought 121.7K shares of Block today

18:44 EST Marin Software jumps 38% to $4.75 after Amazon DSP deal - Shares of Marin Software (MRIN) are up 38% after-hours after the company "announced an integration with Amazon (AMZN) Ads' demand-side platform, or DSP. The integration will allow brands to easily manage, measure, and optimize their Amazon Advertising campaigns - from Sponsored Products, Sponsored Brands, and Sponsored Display to display, video, and audio ads - all within the MarinOne platform. Amazon DSP enables advertisers to programmatically reach Amazon audiences at scale across Amazon sites and apps as well as leading publisher sites and third-party exchanges. This comprehensive inventory allows brands to connect and engage with new and existing customers with relevant, contextual messages across the consumer journey. Advertisers can choose from multiple formats including display, audio, and Streaming TV ads via Fire TV."

18:08 EST Unity Software to partner with Hyundai Motor on new metaverse roadmap - Hyundai Motor (HYMTF) and Unity (U) "announced at CES 2022 a partnership to jointly design and build a new metaverse roadmap and platform for Meta-Factory. The partnership will realize Hyundai's vision of becoming the first mobility innovator to build a Meta-Factory concept, a digital-twin of an actual factory, supported by a metaverse platform. The Meta-Factory will allow Hyundai to test-run a factory virtually in order to calculate the optimized plant operation, and enable plant managers to solve problems without having to physically visit the plant."

17:29 EST BAE Systems, General Dynamics awarded on $337.61M Navy contract - BAE Systems (BAESY) and General Dynamics (GD), were awarded a firm-fixed price, indefinite-delivery/indefinite-quantity, multiple award contract for a combined ceiling of $337.61M for complex repair, maintenance and modernization requirements of non-nuclear Navy amphibious-class ships homeported in or visiting Norfolk, Virginia. These efforts consist of Chief of Naval Operations scheduled docking and non-docking, continuous maintenance and emergent maintenance availabilities of amphibious-class ships to be performed in the Norfolk, Virginia, port. Accordingly, the place of performance is the Norfolk, Virginia, port where the Mid-Atlantic Maintenance Center will administer the contract. Delivery orders will be competitively awarded under this multiple award contract, which are to be performed in Norfolk, Virginia. The contract has an estimated ordering period of five years, which is expected to end in January 2027. No funding will be obligated at contract award. The multiple award contract was competitively procured using full and open competition with six offers received via the beta.sam.gov website. The Naval Sea Systems Command is the contracting activity.

17:18 EST Bell Boeing awarded $1.64B Navy contract for Osprey components - Bell Boeing Joint Program Office (BA) was awarded a not-to-exceed $1.64B firm-fixed-price, performance-based logistics requirements contract for the repair, replacement, required availability, configuration management, and inventory management for supply support for 228 MV-22B; CMV-22 and CV-22 Osprey aircraft components. The contract will include a five-year base period with no options. Work will be performed in Fort Worth, Texas and Ridley Park, Pennsylvania. Work is expected to be completed by December 2026. Annual working capital funds in the amount of $246.56M will be issued for delivery order N00383-22-F-0ZV0 that will be awarded concurrently with the contract and will initially be obligated at the time of award as an undefinitized contract action with a commitment of an additional $82.19M for period of performance from January 2022 through December 2022. Funds will not expire at the end of the current fiscal year. One company was solicited for this non-competitive requirement pursuant to the authority set forth in 10 U.S. Code 2304, with one offer received. Naval Supply Systems Command Weapon Systems Support is the contracting activity.

17:03 EST Compass Minerals says Q1 winter weather activity below prior year, ten-year avg - Compass Minerals "reported that fiscal 2022 first-quarter winter weather activity in its North American-served market was below both prior-year comparable period levels and the ten-year historic average for the comparable period. Due to its previously announced fiscal year-end change, fiscal 2022 first quarter represents the period from Oct. 1, 2021, through Dec. 31, 2021. Historically, the quarterly period ending Dec. 31 represents approximately 28% of the snow events experienced in North America per winter season."

16:55 EST Asur reports December 21 passenger traffic up 5.2% vs December 2019 - Asur announced that passenger traffic for December 2021 totaled 5.5 million passengers, 5.2% above total traffic reported in December 2019. The traffic increase reflects the continued overall recovery in global travel demand, the ongoing rollout of Covid-19 vaccination campaigns in the U.S., and gradual vaccination progress in Mexico, partially offset by government travel restrictions and requirements in certain countries that are intended to contain the spread of the Covid-19 virus. When compared to pre-pandemic passenger levels in December 2019, ASUR's passenger traffic increased 5.1% in Mexico and 11.2% in Colombia during December 2020, while decreasing 1.7% in Puerto Rico. Passenger traffic growth in Mexico and Colombia was driven by both domestic and international traffic increases, while growth in domestic passenger traffic in Puerto Rico did not offset lower international traffic in this market during the same period. This announcement reflects comparisons between December 1 through December 31, 2021, December 1 through December 31, 2020, and December 1 through December 31, 2019. Transit and general aviation passengers are excluded for Mexico and Colombia.

16:46 EST Alteryx to acquire Trifacta for $400M in cash - Alteryx announced it has entered into a definitive agreement to acquire Trifacta, a cloud company that leverages scalable data management and machine learning to make data analytics faster and more intuitive. Alteryx will acquire Trifacta for $400M in cash, subject to customary purchase price adjustments. Alteryx will also establish a retention pool of $75M to be granted in the form of restricted stock units to the former employees of Trifacta. The transaction is expected to close during the first quarter of 2022 and is subject to customary closing conditions. Until the transaction closes, each company will continue to operate independently.

16:46 EST GameStop extends rally, shares up 18% to $154.89 after WSJ report

16:42 EST McEwen Mining not in compliance with NYSE continued listing requirement - McEwen Mining reported that it has fallen below the New York Stock Exchange, or NYSE, continued listing requirement related to the price of its common stock. The NYSE requires that the average closing price of a listed company's common stock be above $1.00 per share, calculated over a period of 30 consecutive trading days. The company was notified by the NYSE on January 5, 2022 that the average price of its common stock for the previous 30 trading days was below $1.00 per share. McEwen Mining intends to take steps to regain compliance with the NYSE continued listing requirements. Under NYSE rules, the company has a period of six months to bring its share price and 30-day average closing share price back above $1.00. During this period, the company's common stock will continue to trade on the NYSE, subject to all other continued listing requirements. At the end of the six-month remedy period, if the share price has not recovered, the company's stock will be subject to NYSE suspension and delisting procedures. The company's listing on the Toronto Stock Exchange is unaffected by any actions of the NYSE.

16:40 EST BuzzFeed names Christian Baesler COO - BuzzFeed named Christian Baesler as COO. Baesler, who will continue to serve as CEO of Complex Networks, joined BuzzFeed when BuzzFeed became a public company and acquired Complex Networks last month. Baesler has overseen the day-to-day operations of Complex Networks and its portfolio of brands since 2018. Prior to that Baesler spent more than a decade at Bauer Media Group.

16:35 EST GameStop jumps 14% to $149.58 after WSJ report of new NFT unit

16:35 EST Adtran stockholders approve business combination with Adva Optical - Adran's stockholders have approved the business combination with Adva Optical Networking by an overwhelming majority. In a special meeting of stockholders held earlier today, a quorum was achieved with 85% of Adtran's outstanding shares represented. Of the voted shares, over 99% were voted in favor of the transaction. The transaction has already been approved unanimously by the Adtran Board of Directors, approved by the Adva Management and Supervisory Boards, who also have recommended to Adva shareholders to accept the offer. The transaction has also received the support of Adva's largest shareholder, Egora, which entered into an irrevocable commitment to tender into the offer shares representing 13.7% of Adva's outstanding shares, and received clearance or confirmation that public review was not needed by all required antitrust organizations. The next milestone will be the close of the initial acceptance period for the tender of Adva shares at midnight on January 12, 2022, and for the combination to be successful, at least 70% of the ADVA shares must be tendered by this time. The parties also continue to work with the relevant authorities to obtain the required foreign direct investment approvals and are confident that such approvals will be obtained in due course.

16:31 EST WWE signs multi-year agreement with International Game Technology - WWE (WWE) "announced that it has signed a multi-year exclusive licensing agreement with International Game Technology (IGT) to develop and distribute WWE-branded omnichannel lottery games and turnkey promotional programs featuring company logos, Superstars, events and programs."

16:20 EST WD-40 CEO 'expects operating environment to remain volatile' - "Our maintenance products delivered solid sales increases in the first quarter including 14 percent growth of WD-40 Multi-Use Product," said Garry Ridge, WD-40 Company's chairman and CEO. "We are pleased with our topline results in the quarter, but we are facing a volatile and challenging environment that is deteriorating our gross margin and causing disruptions to our supply chain." "This is a different game that we're playing and we are using a different playbook. We expect the operating environment to remain volatile and so we are proactively increasing the capacity and resiliency of our supply chain in many of our markets. In addition, in order to navigate the challenging inflationary environment, we are taking the necessary actions to restore our gross margins to historic levels. We're confident that our plans to rebuild margin, when coupled with the advancement of our Must-Win Battles, will enable us to deliver on both our long-term margin and revenue goals," concluded Ridge.

16:19 EST WD-40 reports Q1 gross margin 50.8% vs. 56.4% a year ago

16:18 EST Privia Health names Jeffrey Sherman CFO - Privia Health announced that Jeffrey Sherman will join the company as executive VP and CFO, effective immediately. Sherman will report to Privia Health's CEO, Shawn Morris, and will be responsible for finance and accounting, including financial planning and analysis, treasury, investor relations, and SEC reporting. Sherman had served as executive VP, CFO and treasurer for HMS Holdings since 2014.

16:16 EST Marin Software announces Amazon DSP integration - Marin Software, a provider of digital marketing software for performance-driven advertisers and agencies, announced an integration with Amazon Ads' demand-side platform. The integration will allow brands to easily manage, measure, and optimize their Amazon Advertising campaigns - from Sponsored Products, Sponsored Brands, and Sponsored Display to display, video, and audio ads - all within the MarinOne platform.

16:13 EST Johnson & Johnson reports new results on durability of COVID-19 vaccines in U.S. - Johnson & Johnson announced new results from the largest study to date on the durability of COVID-19 vaccines in the United States, showing that a single shot of the Johnson & Johnson COVID-19 vaccine resulted in long-lasting protection for up to six months against COVID-19 breakthrough infections, hospitalizations, and intensive care unit admissions. The study was sponsored by the Janssen Pharmaceutical Companies of Johnson & Johnson and conducted in partnership with the Department of Science-Aetion, Inc, and the Division of Pharmacoepidemiology, Department of Medicine at Brigham and Women's Hospital and Harvard Medical School. "We continue to undertake extensive efforts to study the durability of protection offered by the Johnson & Johnson vaccine amidst the ever-changing COVID-19 pandemic," said Mathai Mammen, M.D., Ph.D., Executive Vice President, Pharmaceuticals, Janssen Research & Development LLC, Johnson & Johnson. "While these are rapidly evolving data, we are seeing vaccine effectiveness against COVID-19-related hospitalization of approximately 80 percent from a single shot of the Johnson & Johnson vaccine, and this level of protection holds steady across the length of time studied thus far - up to six months. The robust and sustained durability of our COVID-19 vaccine reflects its unique underlying immunology. We previously reported that our vaccine induces a strong antibody response as well as an especially strong increase in T-cells that is consistent across variants, including Omicron." The new study posted on medRxiv comprehensively looked at the durability profiles for all three vaccines authorized or approved in the U.S. using the same methodology across three outcomes of interest: COVID-19 breakthrough infections, hospitalizations, and ICU admissions. The study showed that the effectiveness of the Johnson & Johnson COVID-19 vaccine against breakthrough infections and hospitalizations remained durable. The mRNA vaccines (two-doses) showed waning effectiveness for hospitalizations and breakthrough infections. All three vaccines showed no evidence of waning protection against COVID-19-related ICU admissions at any point, showing strong sustained protection against critically severe disease. The study was not designed to compare the durability of vaccines.

16:12 EST Adverum Biotechnologies appoints Star Seyedkazemi as chief development officer - Adverum Biotechnologies (ADVM) announced that Star Seyedkazemi joined Adverum as the company's chief development officer. Seyedkazemi will serve as a member of Adverum's executive committee and will report to Laurent Fischer, president and chief executive officer at Adverum Biotechnologies. Seyedkazemi will provide leadership for the company's development programs, including global clinical operations, program strategy and project management. Seyedkazemi most recently served as vice president, portfolio management for research and development at Pliant Therapeutics (PLRX).

16:09 EST Terreno Realty reports quarterly operating activity - Terreno Realty Corporation announced its operating, investment and capital markets activity for the fourth quarter of 2021. As of December 31, 2021, Terreno Realty Corporation owned 253 buildings aggregating approximately 15.1 million square feet and 36 improved land parcels consisting of approximately 127.1 acres. In addition, Terreno Realty Corporation had four properties under redevelopment that upon completion will consist of three buildings aggregating approximately 181,000 square feet and two improved land parcels of approximately 12.1 acres. The operating portfolio, excluding two properties under redevelopment, was 95.5% leased at December 31, 2021 to 554 tenants as compared to 98.0% at September 30, 2021 and 97.8% at December 31, 2020. The decline in occupancy as compared to the prior quarter was driven primarily by acquired vacancy of 373,000 square feet (approximately 250bps) of which 361,000 square feet (approximately 240bps) is pre-leased and expected to commence prior to June 30, 2022, and 82,000 square feet (approximately 50bps) from the inclusion of SoDo Row Seattle; The same-store portfolio of approximately 12.5 million square feet was 98.2% leased at December 31, 2021 as compared to 98.6% at September 30, 2021 and 98.0% at December 31, 2020; The improved land portfolio of 36 parcels, excluding two parcels under redevelopment, totaling approximately 127.1 acres was 94.8% leased at December 31, 2021 as compared to 96.1% at September 30, 2021 and 98.6% at December 31, 2021; and cash rents on new and renewed leases totaling approximately 0.6 million square feet commencing during the fourth quarter increased approximately 34.4% with a tenant retention ratio of 57.5%. Cash rents on new and renewed leases totaling approximately 2.6 million square feet commencing during the year ended December 31, 2021 increased approximately 28.4% with a tenant retention ratio of 65.7%.

16:08 EST 4D Molecular says first patient dosed in clinical trial in wet AMD - 4D Molecular Therapeutics announced that the first patient has been dosed in the Phase 1/2 clinical trial of 4D-150 for neovascular age-related macular degeneration, wet AMD. "The dosing of the first patient in the 4D-150 Phase 1/2 clinical trial in wet AMD marks an important milestone for our company and for the patients we aim to serve. 4D-150 is a dual-transgene intravitreal gene therapy incorporating the R100 capsid which we invented through our proprietary Therapeutic Vector Evolution platform," said David Kirn, M.D., Co-Founder and Chief Executive Officer of 4DMT. "We believe that 4D-150's design, which targets four distinct angiogenic factors with dual transgenes, has the potential for broad, robust and durable efficacy after a single low dose intravitreal administration in patients with wet AMD," said Robert Kim, M.D., Senior Vice President and Ophthalmology Therapeutic Area Head of 4DMT.

16:08 EST Azenta names Matthew McManus as COO - Azentahas appointed Matthew McManus COO effective January 17th. McManus was most recently Senior VP and General Manager of the Molecular Diagnostics Division at Bio-Techne following its acquisition of Asuragen, where McManus was President and CEO. Dr. McManus was previously the President and CEO of PrimeraDx.

16:07 EST 4D Molecular says first patient dosed in clinical trial in wet AMD - 4D Molecular Therapeutics announced that the first patient has been dosed in the Phase 1/2 clinical trial of 4D-150 for neovascular age-related macular degeneration, wet AMD. "The dosing of the first patient in the 4D-150 Phase 1/2 clinical trial in wet AMD marks an important milestone for our company and for the patients we aim to serve. 4D-150 is a dual-transgene intravitreal gene therapy incorporating the R100 capsid which we invented through our proprietary Therapeutic Vector Evolution platform," said David Kirn, M.D., Co-Founder and Chief Executive Officer of 4DMT. "We believe that 4D-150's design, which targets four distinct angiogenic factors with dual transgenes, has the potential for broad, robust and durable efficacy after a single low dose intravitreal administration in patients with wet AMD," said Robert Kim, M.D., Senior Vice President and Ophthalmology Therapeutic Area Head of 4DMT.

16:06 EST 4D Molecular says first patient dosed in clinical trial in wet AMD - 4D Molecular Therapeutics announced that the first patient has been dosed in the Phase 1/2 clinical trial of 4D-150 for neovascular age-related macular degeneration, wet AMD. "The dosing of the first patient in the 4D-150 Phase 1/2 clinical trial in wet AMD marks an important milestone for our company and for the patients we aim to serve. 4D-150 is a dual-transgene intravitreal gene therapy incorporating the R100 capsid which we invented through our proprietary Therapeutic Vector Evolution platform," said David Kirn, M.D., Co-Founder and Chief Executive Officer of 4DMT. "We believe that 4D-150's design, which targets four distinct angiogenic factors with dual transgenes, has the potential for broad, robust and durable efficacy after a single low dose intravitreal administration in patients with wet AMD," said Robert Kim, M.D., Senior Vice President and Ophthalmology Therapeutic Area Head of 4DMT.

16:02 EST T-Mobile sees Q4 postpaid account net additions of 315K - T-Mobile reports preliminary Q4 metrics, showing: "315K postpaid account net additions, expected best in industry and highest Q4 in last four years; 1.8M postpaid net customer additions, expected best in industry and highest Q4 in company history; 844K postpaid phone net customer additions, increased year-over-year; 224K High Speed Internet net customer additions, best quarter since launch".

15:56 EST Adtran says stockholders vote in favor of ADVA merger agreement - In a regulatory filing, Adtran disclosed that the company's stockholders voted in favor of adopting the business combination agreement, dated as of August 30, 2021, by and among the company and ADVA Optical Networking SE at a special meeting of its stockholders held on January 6, 2022.

15:07 EST Delta projects 200 daily cancellations Thursday and Friday - Delta Air Lines stated in a post to its corporate news hub: "As severe winter weather continues to hamper U.S. flight operations, including at a number of Delta's largest hubs, a new weather waiver is now in effect for the Northeastern U.S. The waiver impacts three Delta hubs in Boston (BOS) and New York City (JFK, LGA) and 12 Delta-served markets, including the three Washington-area airports (BWI, DCA and IAD). The challenges this winter weather will bring to these major markets, plus the continued impact from the omicron variant, are expected to drive approximately 200 daily cancellations Thursday and Friday between Delta and Delta Connection out of more than 4,000 daily departures across our system." Reference Link

15:02 EST Ionis Pharmaceuticals' eplontersen granted FDA orphan designation - Ionis Pharmaceuticals' eplontersen was granted FDA orphan designation as a treatment of transthyretin-mediated amyloidosis, according to a post to the agency's website. Reference Link

14:24 EST GSK says Canada to buy 20,000 more doses of COVID monoclonal antibody - GlaxoSmithKline (GSK) announced it has signed agreements with the Government of Canada to supply 20,000 doses of Sotrovimab for injection. Sotrovimab is a COVID-19 monoclonal antibody therapy developed by GSK and Vir Biotechnology (VIR). This follows the initial purchase agreement with the Government of Canada to supply 10,000 doses of Sotrovimab, announced on October 4, 2021. That agreement included the option for the Government of Canada to purchase additional doses based on emerging needs.

14:04 EST GM says will be first to use Qualcomm Snapdragon Ride Platform for ADAS - General Motors (GM) announced that its next-generation hands-free driver assist system, Ultra Cruise, will be powered by a scalable compute architecture featuring system-on-chips developed by Qualcomm Technologies (QCOM). GM stated in a press release that it will be the first company to use the Qualcomm Technologies' Snapdragon Ride Platform for advanced driver assistance technology, which features a 5-nanometer Snapdragon SA8540P SoC and SA9000P artificial intelligence accelerator. Ultra Cruise's compute, which is about the size of two laptops stacked together, will first be available in 2023 on the Cadillac LYRIQ and the fully-electric Cadillac CELESTIQ, GM noted. "Despite its relatively small size, Ultra Cruise's compute will have the processing capability of several hundred personal computers. It will take qualities that have distinguished GM's advanced driver assist systems since 2017 to the next level with door-to-door hands-free driving," said Ken Morris, GM vice president of Electric, Autonomous and Fuel Cell Vehicle Programs.

13:52 EST Synaptics debuts Spyder family of video protocol converters - Synaptics announced the Spyder family, the world's first single-chip DisplayPort/USB Type-C-to-HDMI 2.1 and HDMI 2.0 video protocol converters with Power Delivery and Billboard features on chip. The ultra-low-power, tightly integrated solutions address the growing user need to efficiently connect high-resolution, ultra-wide displays with variable refresh rates, VRRs, to PCs, tablets, mobile phones and gaming consoles over DisplayPort or USB Type-C interfaces. Already verified by Intel, AMD and NVIDIA, the small-form-factor ICs provide OEMs and ODMs a compact, cost-effective path to HDMI 2.1 or HDMI 2.0 connectivity using either adapters/dongles or integrated on notebook or PC motherboards.

13:27 EST Rush Street approved to start mobile sports wagering in New York on January 8 - Rush Street Interactive announced that it has been approved by the New York State Gaming Commission to commence mobile sports wagering operations in New York beginning this Saturday, January 8, 2022, at 9:00 am ET. "Upon launch, players across the state aged 21 and over can deposit funds and place bets at the award-winning BetRivers sportsbook on all mobile devices, tablets, desktop and laptop computers," the company stated. Richard Schwartz, CEO of RSI, said, "The long-awaited launch of online and mobile sports betting in New York - the largest online sports betting market by population in the United States - is here, and just in time. With the college football championship game on January 10th and NFL playoffs approaching, and the NBA and NHL seasons in full swing, in addition to countless other sports and betting options available for play, fans have endless entertainment at their fingertips at BetRivers."

12:42 EST Benessere Capital Acquisition seeks extension to stave off liquidation - Benessere Capital Acquisition in a press release last night encouraged its stockholders to vote in favor of the proposal to amend its charter to extend the date by which the company has to complete a business combination from January 7, 2022 to July 7, 2022. A virtual special meeting of the company's stockholders to approve the extension amendment has been adjourned to January 7. Should Benessere not receive votes representing at least 65% of its outstanding shares of common stock, it will need to commence the liquidation process and stockholders "will be unable to capitalize on the potential opportunity presented by the proposed business combination with eCombustible Energy," the company said in a statement.

12:00 EST Humana falls -10.4% - Humana is down -10.4%, or -$47.36 to $408.47.

12:00 EST Heliogen falls -13.8% - Heliogen is down -13.8%, or -$1.35 to $8.41.

12:00 EST Yirendai rises 11.4% - Yirendai is up 11.4%, or 31c to $3.03.

11:50 EST AMC 'on track' to accept Dogecoin, Shiba Inu payments in Q1, says CEO - AMC CEO Adam Aron said via Twitter: "I have been repeatedly asked when AMC expects to routinely accept Dogecoin and Shiba Inu for any and all payments made via the AMC web site and mobile app. I am being told that we are still well on track for the promised Q1 implementation, with exact timing most likely in March." Reference Link

11:07 EST CannTrust reports implementation of CCAA plan, settlement of lawsuits - CannTrust Holdings announced that its Fourth Amended & Restated Plan of Compromise, Arrangement and Reorganization dated July 7, 2021 has been implemented. The implementation of the CCAA Plan follows its approval by the Ontario Superior Court of Justice on July 16, 2021 and the approval of the US class action settlement by the United States District Court Southern District of New York on December 2, 2021. Amongst other steps, the company has contributed $50M to a trust established to facilitate the class action settlements in full satisfaction of the actions against it and $2.7M in trust for settlement of various claims under its CCAA proceedings. As planned, upon the implementation of the CCAA plan, four Directors of the company resigned from the Board of Directors with immediate effect. CannTrust has accepted resignations from Chairman of the Board Robert Marcovitch, along with Directors Mitchell Sanders, Mark Dawber and Shawna Page. "Notwithstanding the significant progress made by the CannTrust Group in these proceedings, including successfully obtaining the reinstatement of its licences from Health Canada, restructuring its operations, resuming production and processing operations, reaching key settlements, and the development, approval and sanction of the CCAA Plan, the Canadian cannabis industry generally, and the CannTrust Group specifically, have faced challenges. As a result, the CannTrust Group does not have sufficient liquidity to operate beyond the near term. CannTrust is in default of the minimum EBITDA covenant under its DIP loan. The DIP lender has not agreed to waive the default although it continues to advance funds under the facility. Despite the implementation of the CCAA Plan, CannTrust's CCAA proceedings are continuing to facilitate further discussions with potential investors and strategic partners, and to develop an orderly wind-down plan to maximize the value of its assets in the event that a financing or strategic transaction option cannot be finalized. The Company's current stay period extends to January 31, 2022."

10:37 EST Bear Cave's Dorsey sees 'problems' at Embark Technology - The Bear Cave's Edwin Dorsey said in a report titled "Problems at Embark Technology" that the company "describes itself as 'an autonomous vehicle company building the software powering autonomous trucks' and merged with a SPAC in November." The company projects no revenue in 2022 and 2023, but $867M in revenue in 2024 and $2.7B in 2025, noted Dorsey, who contends that Embark's current valuation "appears to be based on puffery rather than actual substance." An except from his short report adds: "The company holds no patents, has only a dozen or so test trucks, and may be more bark than bite." In Thursday morning trading, shares of Embark have dropped about 10% to $7.39. Reference Link

10:28 EST Cinedigm to acquire streaming and entertainment company Digital Media Rights - Cinedigm announced that the company has reached an agreement to acquire Digital Media Rights, or DMR, which it calls "a diversified specialty streaming, advertising, and content distribution company with significant expertise in building audiences for global content in North America." DMR focuses on four key streaming businesses with more than 7,500 titles under distribution, has developed and operates 10 channels focused on enthusiast audiences and six of these proprietary streaming services are available as free ad-supported streaming television, or FAST, channels and/or video-on-demand apps, Cinedigm said. "Given DMR's tight programming and demographic alignment with Cinedigm's existing subscription services, the company plans on leveraging each company's respective content portfolio to enhance and broaden the company's existing streaming services. Cinedigm also plans to further expand DMR's Advertising Network," the company stated.

10:00 EST Humana falls -9.4% - Humana is down -9.4%, or -$43.03 to $412.80.

10:00 EST Lamb Weston rises 12.8% - Lamb Weston is up 12.8%, or $8.10 to $71.22.

10:00 EST Vocera rises 26.8% - Vocera is up 26.8%, or $16.76 to $79.28.

09:47 EST ADT Inc. falls -7.2% - ADT Inc. is down -7.2%, or -62c to $8.02.

09:47 EST Vivint Smart Home falls -13.5% - Vivint Smart Home is down -13.5%, or -$1.18 to $7.57.

09:47 EST Lamb Weston rises 10.3% - Lamb Weston is up 10.3%, or $6.49 to $69.61.

09:33 EST Save Foods enters into distribution agreement with BRlev Agricultural Crops - Save Foods, an Israeli Agri-Food Tech company, announced a distribution agreement with Israeli cannabis company BRLev to provide Save Foods' eco crop protection treatment as a white label offering to its global network. Asaf Bardichev, co-founder and CEO of BRLev, commented: "We are very excited to start working with Save Foods to introduce their product to growers and distribute it. Mold is a major problem in the cannabis industry as pesticide use is restricted and chemical additives usually affect the quality and flavor of the plant. With Save Foods' eco crop protection treatment we can reduce crop loss and retain the delicate qualities of the plant."

09:26 EST Camber Energy closes $100M equity transaction with institutional investor - The company states that on December 31, 2021 an institutional investor purchased 10,544 shares of newly designated convertible preferred stock for a purchase price of $100M. CEO James Doris commented, "With the funding commitment in place we can confidently pursue new acquisitions and other important value-added initiatives throughout 2022, yet we have the option of redeeming all or a portion of the shares and not accept the funds if we do not believe it is in the best interest of the company to do so at the particular time. The structure was purposely designed to provide the organization with unprecedented optionality. "

09:20 EST Vinci Partners announces acquisition of Port Terminal 'Porto Pontal' - Vinci Partners Investments announced that Vinci Partners' Infrastructure segment has reached an agreement with JCR Administracao e Participacoes S.A for the acquisition of the container terminal in the state of Parana, Brazil. Porto Pontal marks Vinci Partners Infrastructure team's first investment for its new Transportation and Logistics strategy. The Project's capacity will reach 3M TEUs when fully developed and will require investments of up to R$3B, which will be financed through a combination of equity and debt instruments. Jose Guilherme Souza, partner, and Head of Infrastructure for Vinci Partners, said, "We are very pleased with this new project as it sets an important milestone within our Transportation and Logistics strategy, which we believe has great potential for growth in Brazil, due to its extensive pipeline of investment opportunities in ports and highways. Porto Pontal's main objective is to be placed among the biggest and most efficient container terminals in the country, generating sustainable and positive socioeconomic impact in the state of Parana."

09:17 EST RedHill Biopharma, Gaelan Medical enter license agreement for Talicia for UAE - RedHill Biopharma announced that it has entered into an exclusive license agreement with Gaelan Medical Trade, a wholly owned subsidiary of the Ghassan Aboud Group, for Talicia in the United Arab Emirates. Under the terms of the agreement, RedHill will receive an upfront payment of $2M and is eligible for additional milestone payments as well as tiered royalties up to mid-teens on net sales of Talicia in the UAE. Gaelan Medical will receive the exclusive rights to commercialize Talicia in the UAE, as well as a right of first refusal to commercialize Talicia in the Gulf Cooperation Council region (Saudi Arabia, Kuwait, Qatar, Bahrain and Oman) for a pre-determined period.

09:12 EST Barfresh Food Group announces Roger as new CFO - Barfresh Food Group announced that its Board of Directors has named Lisa Roger as its new CFO. "Roger has extensive public manufacturing company experience and has successfully managed all aspects of finance, most significantly business development and tax strategy, for numerous companies that went from $200M to over $1 billion of annual revenues," the company said.

09:11 EST iFresh provides update on operations - iFresh is providing an update to investors about the status of its operations. As previously disclosed, iFresh was delisted from the Nasdaq Stock Market on November 23, 2021 based on two continued listing deficiencies, so its common stock is currently traded on the OTC Expert Market under the ticker IFMK. While seeking to establish relationships with market makers to provide additional trading opportunities in its stock, the Company is working on returning to compliance with ongoing reporting obligations. Long Deng, Chairman of iFresh, stated, "While iFresh is busy preparing its quarterly and annual reports, I wanted to inform shareholders of several operational updates for the Company. Our subsidiary New York Mart has partnered with Uber to offer online grocery delivery services in New York City. The delivery services will be provided through the Cornershop-powered e-grocery marketplace. After partnering with HungryPanda, a specialist food delivery platform, and Yami, an E-commerce platform, this is the next step forward in our online order integration. In addition, we have entered into a master product supply agreement with Alibaba.com Singapore E-Commerce Private Limited and established a cross-border trade partnership, enabling iFresh to sell American food and products to China via Tmall Global's cross-border e-commerce platform." Long Deng continued: "iFresh's stores in the United States are operating normally. Our management team believes a setback like our delisting has pushed us to focus on shoring up our business fundamentals. We will continue to working on returning to compliance while we communicate with the investors who have supported and believed in us through the years."

09:08 EST 23andMe initiates Phase 1 trial of immuno-oncology antibody - 23andMe announced the first participant has been dosed in a Phase 1 clinical trial evaluating 23ME-00610 for the treatment of advanced solid tumors. 23ME-00610 is 23andMe's first wholly-owned immuno-oncology antibody to enter the clinic. The target for the new investigational antibody, CD200R1, was identified as a promising immuno-oncology target through 23andMe's proprietary genetic and health survey database. "This is an important milestone for 23andMe in our mission to help people access, understand and benefit from the human genome," said Anne Wojcicki, CEO and co-founder, 23andMe. "When we started our Therapeutics group, our goal was to find new medicines validated by human genetics for people with serious unmet medical needs. That's why we're excited to move 23ME-00610 into the clinic to potentially help people with cancer who are in need of new treatment options." The Phase 1 clinical trial is designed to evaluate the safety, tolerability and pharmacokinetics of 23ME-00610 in patients with locally advanced or metastatic solid tumors whose disease has progressed after standard of care treatment.

09:07 EST Pacific Biosciences expands fleet of HiFi applications with Azenta - PacBio announced an expansion of its extensive suite of HiFi applications with Azenta Life Sciences, formerly GENEWIZ. The deal will increase PacBio's HiFi sequencing platforms across Azenta's newly combined company and support Azenta's mission to enable life science companies to deliver impactful breakthroughs and therapies to market faster. "Azenta is a global leader in genomics services, and we're very pleased that our highly accurate HiFi sequencing technology will continue to underpin leading-edge research to build a healthier world for people everywhere," said Christian Henry, Chief Executive Officer and President at PacBio. "With a focus on the future, we are continuing to redefine what is possible in genomics."

09:06 EST CleanSpark reports December bitcoin production of 226 - CleanSpark released its unaudited bitcoin production and operations update for the calendar year-to-date ending December 31, 2021. Bitcoin Production & Operations Update: December monthly production: 226; Calendar year-to-date production ending December 31: 1,528; Total BTC holdings as of December 31: 633; Total BTC converted for operations and growth in CY2021: 909; Currently deployed fleet of over 18,800 latest-generation bitcoin miners with a total hashrate of 1.9 EH/s . The Company sold 414 bitcoin during December 2021 at an average of $49,791 per BTC to support growth and operations. As of the date of this release, daily BTC production has reached a high of 9.5.

09:04 EST Stran & Company secures multi-year contract with national healthcare company - Stran & Company announced that it has secured a multi-year contract with a large nationally recognized healthcare company to provide incentive products and literature designed to help drive consumer health behaviors. The incentive products that will be distributed to the program participants include branded promotional items, educational collateral, and un-branded medical devices that are aimed at driving consumer health behaviors of pregnant women as well as those suffering from hyper-tension or high blood pressure. Andy Shape, President and CEO of Stran, commented, "We are pleased to be selected by this premier healthcare company, which reflects our traction in the market. We believe this selection also validates our ability to address the complex marketing needs of our customers. The healthcare industry is among the top industries utilizing promotional products as a marketing tool to increase brand awareness and engage with consumers. We believe the healthcare market represents a significant, yet largely untapped, opportunity to utilize promotional products to help drive positive and healthy consumer behaviors. We look forward to working closely with this customer and anticipate this contract will drive significant annual revenue for Stran with potential expansion opportunities."

09:03 EST Marrone Bio relocates corporate headquarters to North Carolina - Marrone Bio Innovations announced it has relocated its corporate headquarters from Davis, California, to Raleigh, North Carolina, to support the company's growing presence in markets outside the United States. The move predominantly affects corporate executive positions. Davis will continue to be the hub for the company's research and development operations, along with a number of support functions. "International expansion is a key element of our long-term growth plans, and this move provides us greater proximity to global markets," said Chief Executive Officer Kevin Helash. "We're delighted to be part of the rich agricultural technology community in the Research Triangle area, and look forward to deepening our relationships with partners and customers based in the area. Given the region's extensive agricultural focus, we also anticipate tapping into a talent pool of individuals who will be attracted to the growth opportunities Marrone Bio has to offer."

09:01 EST Amgen, Generate Biomedicines announce research collaboration agreement - Amgen and Generate Biomedicines announced a research collaboration agreement to discover and create protein therapeutics for five clinical targets across several therapeutic areas and multiple modalities. As part of the research collaboration, Amgen will pay $50M in upfront funding for the initial five programs with a potential transaction value of $1.9B plus future royalties, and will have the option to nominate up to five additional programs, at additional cost. For each program, Amgen will pay up to $370M in future milestones and royalties up to low double digits. Amgen will also participate in a future financing round for Generate. Additional terms were not disclosed.

08:57 EST Sensei Biotherapeutics announces two executive promotions - Sensei Biotherapeutics announced two promotions within the company's senior management team. Erin Colgan, formerly senior vice president of finance and administration, has been appointed to chief financial officer. Robert Pierce, M.D., formerly chief scientific officer, has been appointed chief research & development officer and will have additional responsibility for drug discovery, translational medicine, and clinical development of Sensei's pipeline programs.

08:52 EST Calibre Mining reports Q4 gold production 49,218 ounces - Calibre Mining reports operating results for the fourth quarter and year ended December 31, 2021 and 2022 production, sales, and cost guidance. Q4 and Full Year 2021 Production and Sales: Q4 production of 49,218 ounces and sales of 49,207 ounces of gold; and Record production of 182,755 ounces, exceeding high-end of production guidance, and sales of 183,242 ounces of gold. Full Year 2021 Highlights: Announced the acquisition of Fiore Gold in Nevada, creating a diversified, Americas focused, growing mid-tier gold producer; transaction expected to close January 12, 2022; Exceeded the high-end of 2021 production guidance with a strong fourth quarter; Cash as at December 31, 2021 of $78.4 million, an increase of $25.2 million from December 31, 2020; Completed the Pavon Pre-Feasibility Study demonstrating a robust satellite ore source feeding into the Libertad mill which has over 50% surplus capacity; Commenced low-cost open pit mining at Pavon Norte, increased haulage rates quarter over quarter to Libertad, delivering target of 1,077 tonnes per day in September; Announced a 200% increase in year-end 2020 Reserves to 864 koz, representing the largest Mineral Reserve since 2010 with the highest grade on record of 4.49 g/t gold; Advanced technical drilling, land purchases, social and environmental work at the initial resource zones within the Eastern Borosi Project and plan to submit permit applications in early Q1 2022 for open pit and underground operations, leading to expected H2 2023 production growth; 2021 high-grade EBP drill results included: 25.1 g/t gold over 9.7 metres Estimated True Width, 39.2 g/t gold over 3.1 metres ETW, 9.1 g/t gold and 19.9 g/t silver over 6.5 metres ETW, 25.9 g/t gold and 15.3 g/t silver over 1.9 metres ETW, and remains open for expansion; Discovered the high-grade Volcan zone located within 5 kms of the Libertad Mill, results included: 15.6 g/t gold over 4.9 metres ETW and 7.9 g/t gold over 3.4 metres ETW, 11.4 g/t gold over 5.4 metres ETW and 9.26 g/t gold over 1.7 metres and remains open for expansion.

08:44 EST Otonomy expects current capital sufficient to fund operations into H2 of 2023 - The company finished 2021 with approximately $77M in cash, cash equivalents and short term investments and expects that its current capital is sufficient to fund operations into the second half of 2023.

08:40 EST Vaxcyte announces FDA clearance of IND for VAX-24 - Vaxcyte announced that the U.S. Food and Drug Administration, FDA, has cleared the Investigational New Drug, IND, application for VAX-24, its lead, 24-valent pneumococcal conjugate vaccine, PCV, candidate designed to prevent invasive pneumococcal disease. Vaxcyte expects to initiate the VAX-24 Phase 1/2 clinical proof-of-concept study in adults in the first quarter of 2022 and announce topline immunogenicity results by the end of the year. "Clearance of our first IND is an important milestone as we transition to being a clinical-stage company with VAX-24, our lead, broad-spectrum PCV candidate, as it advances into the clinic to generate proof-of-concept data in adults," said Grant Pickering, Chief Executive Officer and Co-founder of Vaxcyte. "We currently expect to deliver topline results from our VAX-24 Phase 1/2 clinical study by the end of 2022, while also continuing to advance the rest of our pipeline including VAX-XP, our PCV candidate with an expanded breadth of coverage of greater than 30 strains."

08:38 EST Air Industries awarded 'Life of the Program Extension' to deliver components - Air Industries Group (AIRI) is pleased to announce that its Sterling Engineering subsidiary has been awarded a "Life of the Program Extension" of a Long-Term Agreement to deliver Turbine Exhaust Case components for the PW-4000 jet engine used on many Airbus (EADSY) and Boeing (BA) commercial aircraft, including the A-330 and Boeing 777. It is anticipated that this contract extension will generate revenue in excess of $6 million over its remaining term. Turbine Exhaust Cases are highly engineered critical components of jet engines. The TEC for the PW-4000 is five feet in diameter. Sterling Engineering has been producing this component for the PW-4000 jet engine for over ten years. Mr. Lou Melluzzo, CEO of Air Industries, commented: "One of the key corporate objectives at Sterling Engineering is to transition a larger percentage of the product mix into long term agreements. Extending this Exhaust Case component for the "life of the program" confirms our customer's confidence that we can produce it competitively and meet their delivery requirements. This award, together with the LTA for the CH-53K helicopter that we announced on October 13th of last year, furthers our progress with the transition of Sterling Engineering's business."

08:37 EST Genasys expands Zonehaven services, alerting resources in California - Genasys announced four additional California counties have entered into multi-year Genasys Zonehaven software services contracts. "Zonehaven's critical evacuation planning, alerting, and real-time life safety information are now available to first responders, emergency services agencies, and the more than 430,000 residents living in Mono, San Luis Obispo, Siskiyou and Sutter counties," the company said. "The hurricane-force winds that drove the most destructive fire in Colorado's history during the last week of December 2021 are further evidence that severe weather and wildfire danger have become year-round hazards in many areas," said Richard Danforth, Chief Executive Officer of Genasys Inc. "By providing first responders and emergency services agencies with vital tools to plan, train for and execute rapid, orderly evacuations, our Zonehaven software services and evacuation management platform helps keep people safe during crisis situations." The Zonehaven platform also incorporates hyperlocal knowledge to model evolving disaster scenarios and subsequent impacts on evacuation zones, traffic patterns and public safety.

08:34 EST Rafael announces completion of dose escalation with no DLT in trial of CPI-613 - Rafael Pharmaceuticals announced the completion of the first cohort of dose escalation with no dose-limiting toxicity, DLT, in the APOLLO 613 Phase 1/2 clinical trial of CPI-613 in combination with hydroxychloroquine in patients with relapsed clear cell sarcoma. Rafael is also launching additional sites for the trial at Seattle Children's and Atrium Health Wake Forest Baptist. Existing sites already enrolling patients include City of Hope in Duarte, California, Cleveland Clinic Children's, University of Michigan's Rogel Cancer Center and Vanderbilt University Medical Center. "The success of our first cohort of dose escalation increases our optimism that devimistat may help address the gaps for efficacious treatment methods for relapsed clear cell sarcoma," said Sanjeev Luther, President and CEO of Rafael Pharmaceuticals. "There is a significant unmet need in treatments for clear cell sarcoma and other rare cancers, and as such, patients and physicians in the rare disease community are incredibly hopeful of devimistat's capabilities."

08:32 EST Esports Technologies files patent for performance-based betting system - Esports Technologies announced the filing of a new patent application for a "Financial Instrument Performance-Based Pari-Mutuel Betting System and Method." The system and method implements an electronic betting experience for an event that is comparable to horse racing, but using a group of financial instruments. The system and method allows bettors to place bets on which "participant" from the pool of financial instruments will win over a fixed period of time. Bets can be placed through the system up until a set time endpoint. The system places all the wagers in a pari-mutuel pool and calculates new odds based on the size of each bet. The system pays out based on the finishing position of each item in the pool.

08:30 EST Enfusion promotes Iris Xinwei Wang to chief strategy officer - Enfusion announced two internal executive promotions. Iris Xinwei Wang will serve as Enfusion's chief strategy officer, based in New York. Additionally, Lotte Tonsberg will serve as the London-based Head of Sales for EMEA. As chief strategy officer, Iris will serve as the driver of Enfusion's continued strategic expansion, corporate development and transformation.

08:29 EST Harsco renews contract with JSIS in Oman - Harsco announced that its Harsco Environmental division has renewed their contract with Jindal Shadeed Iron and Steel, JSIS, a leading iron and steel producer in Oman. "Renewing their contract with Harsco Environmental allows JSIS to focus on their production while knowing their slag is being handled and utilized for different applications in an environmentally friendly way," the company said. "Harsco Environmental is pleased to continue its services with Jindal Shadeed Iron and Steel. JSIS is a key steel producer and one of our valued customers in the Middle East. I am confident our relationship will continue to grow as JSIS expands," said Russ Mitchell, Vice President and Chief Operating Officer of Harsco Environmental. Harsco Environmental will continue to provide slag management and metal recovery as well as skull processing services for JSIS over the next five years.

08:27 EST Horizon Therapeutics to be tenant at Alexandria Center in Maryland - Horizon Therapeutics announced that it has signed a long-term, full-building lease with Alexandria Real Estate Equities to be the first tenant at the Alexandria Center at Traville Gateway campus in Rockville, Maryland. When completed, the facility will serve as the company's primary East Coast research and development and technical operations hub. Construction at the 192,000-square-foot site is underway and Horizon expects to start work on interior improvements in 2023. Additional terms of the agreement were not disclosed.

08:26 EST Sundial Growers agrees to improve consideration to Alcanna shareholders - Sundial Growers has agreed to improve the consideration to be provided to Alcanna shareholders for their common shares of Alcanna pursuant to the previously announced plan of arrangement by including a cash component. The revised consideration provides that Alcanna shareholders will receive, for each Alcanna Share held, 8.85 common shares of Sundial and $1.50 in cash consideration. The revised consideration represents a deemed value of approximately $8.43 per Alcanna Share. The deemed value implies an approximate 15.3% premium from the closing price of Alcanna Shares on the TSX as of January 5, 2022. The special meeting of Alcanna Shareholders remains scheduled on January 7 to consider, and if deemed advisable, to pass a special resolution approving the Arrangement, as amended. Alcanna's board of directors has unanimously approved the revised consideration and the amendment to the arrangement agreement and recommends that Alcanna shareholders vote in favor of the arrangement resolution. The record date for determining the Alcanna shareholders eligible to vote at the Meeting remains the close of business on November 9, 2021.

08:25 EST Bed Bath & Beyond expects conditions to continue to remain 'complex'

08:24 EST France fines Google EUR 150M over privacy breaches - French authorities hit Google with a EUR 150M fine over privacy breaches. In a statement published on Thursday, French data protection authority CNIL said Google's search engine and its subsidiary YouTube had not made it simple enough for French users to reject cookies, relative to how easy it was to accept them. Reference Link

08:22 EST Beam announces City of San Luis Obispo, CA deploys EV ARC charging system - Beam Global announced that the County of San Luis Obispo in California has deployed the EV ARC solar-powered EV charging system to charge County fleet EVs. The system was purchased through the California Contract #1-18-61-16 which simplifies the procurement process and ensures best pricing. The County of San Luis Obispo's EV ARC system fits in a standard parking space, without reducing available parking, and is equipped with three Enel X JuiceBox(R) Pro EV charging stations. The EV ARC system generates and stores its own clean electricity and delivers that electricity to power EVs, day or night, and during inclement weather and power outages. "Energy resiliency is fast becoming a critical consideration for EV charging infrastructure in the wake of extreme weather, related power outages or shutdowns, and increasing strain on the U.S. electric grid," said Beam Global CEO Desmond Wheatley. "The County of San Luis Obispo joins over 100 forward-thinking municipalities and organizations in proactively planning ahead by deploying off-grid, renewably powered EV ARC EV charging systems. We note that federal, state and local governments are putting increasing emphasis on resilient EV charging as electricity becomes vital fuel for their fleet vehicles."

08:19 EST Bed Bath & Beyond: Revenue momentum below expectations in Q3 - Notes "slower" start to sales in September, October. Comments taken from Q3 earnings conference call.

08:16 EST Ritchie Bros. and Nations Capital to acquire and sell road maintenance equipment - Ritchie Bros. announced that Nations Capital, an asset management and advisory firm focused on opportunistic investments and asset remarketing, together with Ritchie Bros. has entered into an agreement to acquire certain assets formerly owned by DBi Services in a transaction with DeAngelo Contracting Services, or DCS. The assets were recently acquired by DCS and deemed excess to the ongoing needs of its business units. The assets include several thousand units of highway and road maintenance equipment including service vehicles, trucks, construction equipment and miscellaneous support equipment located across the United States. All assets will be consolidated to locations controlled by Ritchie Bros. and NCI and offered to their customer base and interested parties via bulk private sale and auctions.

08:14 EST Bolt doses first patient with BDC-1001 in combination with OPDIVO - Bolt Biotherapeutics (BOLT) announced that the first patient has been dosed in a new combination arm of the ongoing multi-center, multi-dose Phase 1/2 clinical trial of BDC-1001. This arm is evaluating BDC-1001 in combination with Bristol Myers Squibb's (BMY) PD-1 checkpoint inhibitor OPDIVO. BDC-1001 is a HER2-targeting Boltbody immune-stimulating antibody conjugate in development for the treatment of patients with HER2-expressing solid tumors. "We are excited to evaluate BDC-1001 in combination with nivolumab, a leading PD-1 checkpoint inhibitor. Pairing BDC-1001's mechanism of action with the checkpoint inhibitor approach has the potential to yield a stronger, targeted modulation of the immune system. Initial safety and early efficacy findings reported from the ongoing monotherapy arm of the Phase 1/2 clinical trial make BDC-1001 a potentially promising candidate for the treatment of patients with HER2-expressing solid tumors," said Edith Perez, M.D., Chief Medical Officer of Bolt Biotherapeutics.

08:13 EST DarioHealth wins two digital therapeutics contracts within employer market - DarioHealth announced two new contracts to provide its digital therapeutics beginning in Q1. The new clients include a large Northeast regional employer in the finance industry set to deploy Dario's full suite of solutions, and a Northeast regional employer in the food industry contracted to deploy Dario's digital therapeutic solution for diabetes. Dario's digital therapeutics platform provides support for people living with diabetes, pre-diabetes, hypertension, weight management, musculoskeletal and behavioral health needs.

08:12 EST I-Mab announces senior management team share purchase plan - I-Mab announced that the senior management team of the company, including Founder, Chairman and Acting CEO Dr. Jingwu Zang, President Dr. Andrew Zhu, CFO John Long, Chief Strategy Officer Jielun Zhu and Chief Business Officer Dr. Weimin Tang, have informed the company of their intention to use their personal funds to purchase the company's American depositary shares on the open market for an aggregate amount of minimum $3M and up to $20M no later than February 28.

08:10 EST Axcelis announces multiple shipments of Purion Power Series implanters - Axcelis announced follow on shipments in Q3 and Q4 of the company's Purion H200 SiC Power Series high current implanters to a leading power device chipmaker. The shipments went to multiple fabs located in Asia and Europe. In Q4, Axcelis also closed a Purion XE Power Series SiC high energy implanter evaluation for a new customer penetration in Europe. The systems at both customers will be used in high volume production of SiC power devices supporting automotive device markets.

08:08 EST Stryker agrees to acquire Vocera for $79.25 per share

08:07 EST Enterprise Products increases quarterly dividend to 46.5c per share - Enterprise Products Partners announced that the board of directors of its general partner declared the quarterly cash distribution paid to limited partners holding Enterprise common units with respect to the fourth quarter of 2021 of 46.5c per unit, or $1.86 per unit on an annualized basis. The quarterly distribution will be paid Friday, February 11, , to common unitholders of record as of the close of business Monday, January 31 .This distribution represents a 3.3 percent increase over the distribution declared with respect to the fourth quarter of 2020. In addition, during the fourth quarter of 2021, Enterprise purchased $125M of its common units in the open market, bringing the total amount of common unit buybacks during 2021 to $200M. Including these repurchases, Enterprise has utilized 24% of its $2B buyback program authorized in January 2019.

08:06 EST Leidos names Terry Phillips as Chief Security Officer - Leidos announced the appointment of Terry Phillips as the company's Senior Vice President and Chief Security Officer. Phillips will be responsible for leading, managing and directing the activities of the Leidos Global Security Organization. He will also oversee the company's compliance with U.S. and foreign government national security standards. Prior to joining Leidos, Phillips served as Executive Director of the Air Force's Office of Special Investigations Office of Special Projects.

08:04 EST Atlas Air purchases four Boeing 777 Freighters - Boeing (BA) and Atlas Air (AAWW) announced an order for four 777 Freighters. The order, placed in December, rounds out a record-setting 2021 for Boeing's freighter family including new-production and converted models. Boeing has forecast that the global freighter fleet will grow by 70% in the next 20 years, with freight carriers such as Atlas Air supporting a rapidly expanding global e-commerce business and evolving supply chains.

08:03 EST Saia signs LOI to purchase, lease up to 100 Nikola zero-emission trucks - Nikola announced a collaboration with Saia LTL Freight to accelerate the implementation of heavy-duty electric transportation trucks. This collaboration includes a Letter of Intent to purchase or lease 100 Nikola Tre heavy-duty battery electric vehicles following the satisfactory completion of a demonstration program. The demonstration program will include three BEV trucks to be operated in separate locations across the Saia network and is expected to begin in the first half of 2022. Deliveries of 100 production vehicles are intended to occur between 2022 and 2024 with the initial 25 targeted for 2022.

07:58 EST Terns appoints Jasper as SVP, head of research, Chung as SVP, CDO - Terns Pharmaceuticals announced the appointment of Jeffrey Jasper, Ph.D., as senior vice president, SVP, head of research. Dr. Jasper joins Terns with more than 28 years of experience in the biopharmaceutical industry. Terns also announced the promotion of Diana Chung to senior vice president, chief development officer, CDO. Both Dr. Jasper and Chung will report to Erin Quirk, M.D., president, head of research and development and chief medical officer.

07:55 EST Cyclacel Pharmaceuticals announces business objectives for 2022 - Cyclacel Pharmaceutical provided a business update reviewing 2021 achievements and outlining the Company's key business objectives for 2022. "This past year proved to be very productive for Cyclacel as we achieved our planned business objectives," said Spiro Rombotis, President and Chief Executive Officer. "First and foremost, we initiated two registration-directed, Phase 1/2 trials for our lead candidate fadraciclib, an oral CDK2/9 inhibitor. These studies are assessing fadraciclib activity across a range of solid tumors and hematological malignancies. In the solid tumor study we are enrolling patients at the third dose level using a schedule of twice daily dosing for five days, for 3 out of 4 weeks. In the leukemia study we are enrolling patients at the initial dosing level. We have also completed FDA review of an Investigational New Drug Application of CYC140, a differentiated oral PLK1 inhibitor, and received clearance to proceed with a registration-directed Phase 1/2 study in solid tumors. Finally, we strengthened our balance sheet in the year which provides a cash runway until early 2023." Key Business Objectives for 2022: First patient to be dosed with oral CYC140 in the 140-101 solid tumor study; Initial data from Phase 1 dose escalation of the 065-101 solid tumor study of oral fadraciclib; First patient to be dosed with oral CYC140 in the 140-102 leukemia study; Commence Phase 2 proof of concept stage in the 065-101 solid tumor study of oral fadraciclib; Initial data from Phase 1 dose-escalation of the 065-102 leukemia study of oral fadraciclib; Commence Phase 2 proof of concept stage of oral fadraciclib in the 065-102 leukemia study

07:50 EST Avalo Therapeutics reports data from Phase 1b for AVTX-002. program updates - Avalo Therapeutics provides a comprehensive update on the Company's growth opportunities and mid-stage development portfolio. Program Updates and Key Highlights: AVTX-002 Phase 1b Crohn's Disease Clinical Trial Results: The Phase 1b study evaluated the safety, tolerability, pharmacokinetics, and short-term efficacy of AVTX-002 in adults with moderate to severe, active CD who have previously failed anti-tumor necrosis factor alpha treatment. Clinically meaningful mucosal healing, determined by colonoscopy and adjudicated by a central reader, was observed in fifty percent of subjects. Seventy-five percent of patients that demonstrated mucosal healing by colonoscopy reported they had returned to doing poorly two to three months after cessation of study drug, suggesting a drug-related effect; follow-up is ongoing for the remaining responder. Data continued to show that treatment with AVTX-002 was safe and well tolerated with no drug-related serious adverse events observed. Avalo continues to evaluate the biomarker data from this study. The Company is currently evaluating AVTX-002 in a cohort of ulcerative colitis patients with moderate to severe UC who are refractory to biologic therapy, including anti-TNFalpha, with data anticipated in the third quarter of 2022. AVTX-002 for the treatment of non-eosinophilic asthma: An investigational new drug application has been cleared by the FDA. The Company expects top-line data from the randomized, double-blind, placebo-controlled Phase 2 clinical trial in 80 patients with poorly-controlled NEA in the second half of 2022. AVTX-007 in Multiple Myeloma and Adult Onset Still's Disease: Multiple Myeloma: The Phase 1b study of AVTX-007 is nearing completion. Three doses of AVTX-007 as a single agent were evaluated. AVTX-007 was generally safe and well tolerated, but no efficacy signal was seen in the high dose cohort or expansion phase. Based on these results, the company is discontinuing the multiple myeloma program. AOSD: AVTX-007 is being evaluated in a multicenter, Phase 1b study in 12 refractory or steroid-dependent patients with AOSD in two cohorts. Top-line data for both cohorts of the trial are anticipated by mid-year 2022. AVTX-800 programs for Congenital Disorders of Glycosylation: Avalo plans to initiate the study of AVTX-803 in patients with leukocyte adhesion deficiency type II caused by loss-of-function mutation in the SLC35C1 gene in the first quarter of 2022, with data expected in the third quarter of 2022. The Company remains in dialogue with the FDA to align on suitable clinical study designs for AVTX-801 and AVTX-802. AVTX-006 in Complex Lymphatic Malformations: The Company expects top-line data from its Phase 1b proof-of-concept of AVTX-006 for complex lymphatic malformations in mid-year 2022. AVTX-006 has received ODD and RPDD making it eligible for Priority Review Voucher upon approval.

07:44 EST Rekor Systems chosen by City of Winchester, VA to provide traffic solutions - Rekor Systems has been chosen by the City of Winchester, Virginia to provide AI-powered infrastructure solutions. The Rekor One intelligence platform delivers Traffic Management and Public Safety solutions that serve multiple missions for the City of Winchester. Rekor One was chosen for a six-month pilot. "The platform includes a suite of integrated solutions that support multiple management functions to enhance the safety and quality of life for the City's citizens," the company said. Rekor recently announced a similar pilot in Chattanooga, Tennessee. At the conclusion of the pilot, the City of Winchester can, at its sole discretion, choose to transition to a comprehensive annual subscription model priced at $455,000 per annum for the nine-square-mile city. This subscription would cover all elements of the pilot along with the implementation of additional traffic sensors, soft infrastructure, and requisite training needed. Official terms are subject to final negotiations. "Winchester had a very clear vision of what it needed to understand about their roadways to better serve their citizens," said Robert Berman, President and CEO, Rekor. "Rekor One delivers a full solution that meets and even exceeds the City's requirements and can be implemented quickly and easily."

07:41 EST Crown Electrokinetics Smart Window Inserts selected by Hudson Pacific Properties - Crown Electrokinetics has finalized an agreement with Hudson Pacific Properties to install energy-saving Smart Window Inserts at several office properties across its West Coast portfolio. The inserts, which are solar-powered and can be retrofitted to existing window frames, will provide additional insulation and allow Hudson Pacific tenants to transition their windows from clear to dark in seconds. This emerging property technology, or proptech, has the potential to cut energy consumption and carbon emissions from heating and cooling systems by 26%, according to Crown's initial field testing.

07:39 EST Bed Bath & Beyond pursuing additional expense optimization measures - CEO Tritton said, "In response to a sharp increase in inflation and pervasive freight and supply chain headwinds, we swiftly implemented market-driven pricing, promo optimization and product mix plans. Our decisive actions led to an adjusted gross margin rate significantly exceeding plan and above 2020 and 2019 - a key financial barometer of our three-year transformation strategy. Our Owned Brands also continued to produce higher merchandise margins at increased penetration rates. We now intend to expand the Owned Brands strategy to BABY in 2022 as we look at margin enhancing strategies, given sales results in this business have stabilized as a result of our targeted efforts to improve this banner. We are identifying exciting new opportunities to drive sales and BABY is an important cornerstone of our plans, including our recently announced collaboration with Kroger and our own digital marketplace. Just as we delivered on gross margin during the quarter, our holistic focus is on improving our top and bottom line results as we continue to transform. While we continue to target sales improvement, we are also focused on SG&A. We are pursuing additional expense optimization measures of approximately $100 million annualized that will explore areas such as store fleet optimization, fixed costs and discretionary savings opportunities. Earlier this quarter we also announced that we expect to complete our $1 billion three-year share repurchase plan by the end of fiscal 2021, two years ahead of schedule, which underscores our ongoing confidence in our turnaround and commitment to our capital allocation framework. Having concluded just the third quarter of our multi-year plan, we will continue to execute our strategic transformation by diagnosing and reforming our legacy business to achieve our goals. As we prepare for 2022, we look forward to operating in a normalized environment with a base of business upon which to grow."

07:38 EST Bed Bath & Beyond: November comp sales down mid-single digits - Bed Bath & Beyond, in slides that will be presented on its Q3 earnings conference call, said comp sales improved within the fiscal quarter. Fiscal November comp sales were down mid-single digits, while fiscal quarter sales fell high-single digits.

07:33 EST Williams delivers record amount of gas on Transco interstate pipeline - Williams announced that it recently delivered a record amount of natural gas on its Transco interstate pipeline, providing essential and reliable service to natural gas distribution companies, electric power generators, LNG exporters and other customers located along the Eastern Seaboard and Gulf Coast. Transco, the nation's largest-volume natural gas transmission system, delivered a record-breaking 17.15M dekatherms on January 3. The new peak-day mark surpasses the previous high that was set on February 20, 2020. While extreme winter weather usually coincides with peak-day deliveries, the volume record this week was due to continued expansions on Transco to serve the growing demands for U.S. natural gas. To meet this demand, Williams has nearly tripled contracted capacity on Transco to approximately 18.7 MMdt/d in 2021 primarily through incremental growth projects along Transco's existing footprint. Leidy South was the most recently completed expansion project to maximize the use of Transco's existing corridor and minimize environmental impacts.

07:32 EST Bed Bath & Beyond reports Q3 SSS down 7% - Mark Tritton, Bed Bath & Beyond's President and CEO said, "During a quarter where our sales momentum was not where we wanted it to be with sales of $1.9 billion and a 7% comp decline, improved momentum in November and strong gross margins demonstrated progress in our transformation. After our previously announced slower start to sales in September and October, we drove a change in trends by November with our comp decline improving, particularly in stores. However, overall sales were pressured despite customer demand due to the lack of availability with replenishment inventory and supply chain stresses that had an estimated $100 million, or mid-single digit, impact on the quarter and an even higher impact in December. Nevertheless, our customer acquisition strategy for the Bed Bath banner is gaining traction as evidenced by our Beyond+ loyalty program, which grew by nearly half a million members after one of our largest new subscriber quarters. Our buybuy BABY banner continues to deliver double-digit growth and we are on track to achieve approximately $1.3 billion in sales in this first year of transformation - ahead of our investor day goals - all while improving profitability and market share."

07:26 EST TopBuild acquires Insulating Products - TopBuild has acquired Insulating Products, a residential and light commercial insulation distribution company headquartered in Lewisville, Texas with additional facilities in Houston, San Antonio, Oklahoma City and Wichita. Robert Buck, President and CEO of TopBuild, noted, "Insulating Products will enhance the strength of our specialty distribution business as it brings a strong and long-standing customer base and expands our geographic presence in the high growth Southwest region."

07:24 EST Constellation Brands enters brand authorization agreement with Coca-Cola - Constellation Brand (STZ;STZ.B) announced that it has entered into a brand authorization agreement with The Coca-Cola Company (KO) in the United States to bring the FRESCA brand into beverage alcohol through the manufacturing, marketing, distribution, and launch of FRESCA Mixed - a new line of spirit-based, ready-to-drink cocktails that are well-aligned to a number of emerging consumer trends. "The Coca-Cola Company's FRESCA brand is not only trusted by consumers, but also directly delivers on consumer preferences for refreshment, flavor, and convenience - attributes that also play well within beverage alcohol and where we can leverage our expertise," said Bill Newlands, Constellation's president and chief executive officer. FRESCA Mixed is expected to launch this year, starting with cocktails using real spirits. The products will be produced and marketed by Constellation and distributed through Constellation's 3-tier distribution networks.

07:22 EST Plus Therapeutics expands investigational oncology drug pipeline - Plus Therapeutics announced that it has entered into an agreement with The University of Texas Health Science Center at San Antonio for a worldwide exclusive license to develop and commercialize novel interventional therapeutics for cancer. The licensed patents include composition of matter patents for biodegradable alginate microspheres, BAM, containing nanoliposomes loaded with imaging and/or therapeutic payloads. Therapeutic payloads may include radiotherapeutics, chemotherapeutics or thermotherapeutics. The financial terms of the exclusive license agreement are primarily success-based with milestone and royalty payments contingent on achieving key clinical, regulatory and sales milestones. The Company will initially focus on developing 188RNL-BAM as a next-generation radioembolization therapy for liver cancer, in which BAM blocks the hepatic artery segments that supply blood to the malignant tumor while also providing 188RNL radiotherapy by directly irradiating the tumor. "This transaction is the next step in our plan to expand our pipeline using precision, targeted radiotherapeutics," said Norman LaFrance, M.D., Chief Medical Officer of Plus Therapeutics. "Next steps are to complete and compile the promising preclinical work performed thus far and prepare for an IND submission in 2022 for the treatment of liver cancer."

07:19 EST Anavex promotes Kaufmann to CSO, Hammond to CMO - Anavex Life Sciences announced that Walter Kaufmann, M.D. has been promoted to Chief Scientific Officer, CSO, and Edward Hammond, M.D., M.P.H., PhD, has been appointed Chief Medical Officer, CMO, effective immediately. Before joining Anavex over three years ago, Dr. Kaufmann was the Director of the Center for Translational Research at the Greenwood Genetic Center. Dr. Hammond, who joined recently, is a Physician-Scientist, Clinical Epidemiologist and Public Health practitioner.

07:17 EST Kirkland's announces new $30M share repurchase plan - Kirkland's announced that its board of directors has authorized a new share repurchase plan providing for the purchase in the aggregate of $30M of the company's outstanding common stock.

07:17 EST Kirkland's reports 2021 holiday SSS down 6.4% - Comparable sales for the fiscal fourth quarter through December 2021 decreased 6.4% compared to the same prior-year period. This includes a 9.5% comparable sales decrease for November 2021 and a 3.3% decrease for December 2021, both compared to the same prior-year period.

07:13 EST Curis' CA-4948 monotherapy shows positive activity in Phase 1/2 AML study - Curis announced positive updated clinical data from the ongoing open label Phase 1/2 dose escalation and expansion study of CA-4948, a novel, small molecule IRAK-4 inhibitor, as a monotherapy in patients with relapsed or refractory - R/R - acute myeloid leukemia, or AML, or high risk myelodysplastic syndromes - MDS -. As of December 16, 2021, 49 total patients had been administered CA-4948 in the R/R AML/MDS study. The safety profile to date showed key findings: CA-4948 was well-tolerated across multiple dose levels; treatment-related adverse events were reversible and manageable; no dose-limiting myelosuppression; no cumulative toxicities observed; no grade 4 or 5 treatment-related adverse events. The company believes these attributes of CA-4948's emerging safety profile may provide an advantage compared to current standard of care therapies in monotherapy and could also make CA-4948 an attractive candidate for addition to combination therapy regimens. Previous data presented by Curis in June 2021 highlighted preliminary efficacy data of CA-4948 in R/R AML/MDS patients whose disease is characterized by spliceosome or FLT3 mutation. The clinical data update provides an expanded data set for this genetically-defined patient population and further support the rationale for seeking a discussion with FDA in the first half of 2022 to discuss the potential for a rapid registrational path forward for CA-4948 as a monotherapy in genetically-defined patient populations. The company believes the data suggest a favorable safety and anti-cancer activity profile compared to standard of care therapies for these patient populations. Enrollment in the study of CA-4948 in R/R AML/MDS is on-going, and Curis looks forward to potential discussions with the FDA in the first half of 2022 regarding the potential for a rapid registrational path forward for CA-4948 as a monotherapy in genetically-defined patient populations. Curis expects to provide additional data from the R/R AML/MDS study at a medical meeting in 2022.

07:11 EST Finch Therapeutics announces two new US patents granted for FIN-211 - Finch Therapeutics announced that the U.S. Patent and Trademark Office has issued two new patents covering the company's FIN-211 enriched consortia microbiome product candidate in development for children with autism spectrum disorder, ASD, and significant gastrointestinal, GI, symptoms. The company's intellectual property portfolio now includes 59 issued U.S. and foreign patents with more than 130 patent applications pending. The first patent covers technologies involved in addressing ASD and GI symptoms associated with ASD by orally administering a donor-derived microbial community enriched with bacterial isolates from a genus with potential therapeutic applications in ASD. This patent is jointly owned with, and exclusively licensed from, the Arizona Board of Regents on behalf of Arizona State University and the Regents of the University of Minnesota. The second patent, solely owned by Finch, covers encapsulated compositions containing donor-derived microbiota enriched with one or more cultured bacterial strains, and methods of manufacturing such compositions. The first and second patents have expiration dates in 2036 and 2031, respectively. Mark Smith, PhD, Chief Executive Officer of Finch Therapeutics said, "We believe FIN-211 has the potential to promote the broad functions of a diverse gut microbiome while also targeting specific mechanisms that may be important in ASD. We look forward to initiating our Phase 1b trial of FIN-211 in children with ASD and constipation in the first half of 2022, research that we believe will add to the growing body of evidence supporting the potential for a microbiome-based therapeutic option for children with ASD and significant GI symptoms."

07:09 EST Intema receives proceeds of $1.57M from warrants, reports annual meeting result - Intema Solutions announces that it has received proceeds of $1,574,400 from the exercise of warrants into 13,120,000 common shares of the Corporation. Intema also reports on the outcome of its annual general and special meeting of shareholders, held on Tuesday, January 4, 2022 At the meeting, the Corporation's shareholders approved all the resolutions set out in the management proxy circular dated December 6, 2021, including those on the election of directors, the appointment of MGO LLP as the new auditors of the Corporation for the coming year and the approval of a 10% rolling stock option plan. The shareholders also approved the name change of the Corporation to React Gaming Group, which will become effective at the closing of the transaction with Livestream Gaming.

07:08 EST Synlogic announces progress toward 2022 clinical milestones - Synlogic provided an update on progress towards multiple 2022 clinical milestones. "The past year was transformational for Synlogic as we achieved clinical proof of concept in phenylketonuria, a disease that causes tremendous burden to all of those affected. Current treatments leave a need for a safe, effective, and convenient oral treatment option and we are thrilled to be on track to begin the pivotal Phase 3 program in the second half of 2022," said Aoife Brennan, M.B. Ch.B., Synlogic President and Chief Executive Officer. "Our plans for 2022 will build on this progress with multiple clinical data readouts expected across our programs." Clinical Programs and Anticipated 2022 Milestones: Synlogic's research collaboration with Roche to develop a Synthetic Biotic drug candidate for the treatment of inflammatory bowel disease is continuing with the potential for additional research milestones during 2022. Synlogic and Ginkgo are also advancing their research collaboration to include additional, undisclosed preclinical assets. Expected clinical milestones across these programs include: Rare Metabolic Diseases: SYNB1618 and SYNB1934 for PKU - Data from the Phase 2 SynPheny-1 study H1 2022 and Phase 3 trial initiation H2 2022. SYNB1353 for HCU - Data from Phase 1 trial in healthy volunteers H2 2022. Enteric Hyperoxaluria: SYNB8802 for enteric hyperoxaluria - Proof of concept in 2022.

07:07 EST Regenxbio announces FDA clearance of IND for clinical trial of RGX-202 - Regenxbio announced the clearance of its Investigational New Drug application by the United States FDA to evaluate RGX-202, a potential one-time gene therapy for the treatment of Duchenne muscular dystrophy in a first-in-human clinical trial. RGX-202 is designed to deliver a transgene for a novel microdystrophin that includes the functional elements of the C-Terminal domain found in naturally occurring dystrophin. RGX-202 uses Regenxbio's proprietary NAV AAV8 vector. Regenxbio plans to initiate the trial in the first half of 2022.

07:05 EST Vitalhub announces Royal Berkshire NHS licenses patient flow platform - VitalHub announces a licensing transaction of subsidiary Intouch with Health's patient flow platform to Royal Berkshire NHS Foundation Trust. The transaction is principally focused on Royal Berkshire Hospital and allows the licensed solutions to be used at all 6 Trust sites. "This is evidence that our acquisition strategy which focuses on synergistic solutions is working to improve health outcomes, system-wide, for our customers. The Royal Berkshire's investment in improving the outpatient experience and the success of our business in 2021 underlines that there is a significant opportunity to grow our leadership position in the outpatient flow optimization category. The Intouch platform continues to be the leading patient flow system in the UK market," said Dan Matlow, CEO of VitalHub Corporation.

07:02 EST Biohaven Pharmaceutical reports Q4 preliminary NURTEC ODT revenue $190M - Based on preliminary unaudited financial information, the company reported approximately $190M in net product revenue from sales of NURTEC ODT in the fourth quarter of 2021 and approximately $462M in net product revenue for 2021. There were no material changes in channel inventory days over the course of the year.

06:52 EST The Buckle reports December 2021 sales up 17.7% year-over-year - The Buckle announced that comparable store net sales, for stores open at least one year, for the 5-week period ended January 1, 2022 increased 17.7% from comparable store net sales for the 5-week period ended January 2, 2021. Net sales for the 5-week fiscal month ended January 1, 2022 increased 17.3% to $198.7M from net sales of $169.4M for the prior year 5-week fiscal month ended January 2, 2021. Comparable store net sales year-to-date for the 48-week period ended January 1, 2022 increased 46.7% from comparable store net sales for the 48-week period ended January 2, 2021. Net sales for the 48-week fiscal period ended January 1, 2022 increased 46.7% to $1.230B from net sales of $838.2M for the prior year 48-week fiscal period ended January 2, 2021.

06:50 EST Helen of Troy sees FY22 capital asset expenditures $85M-$110M

06:34 EST Trane's Chief Human Resources, Marketing and Communications officer retiring - Trane Technologies' Executive VP and Chief Human Resources, Marketing and Communications officer Marcia Avedon has announced her planned retirement from the company in April after 15 years of service. Mairead Magner has been named Senior Vice President and Chief Human Resources Officer, and Carrie Amendum Ruddy has been named Senior VP and Chief Communications and Marketing Officer, effective immediately. Avedon has served as Chief Human Resources Officer since 2007, also overseeing the company's communications, marketing and government relations functions. Avedon will work over the next few months to support a smooth transition of responsibilities to Magner and Ruddy. Magner has spent her entire career with the company, joining in 1998 through a human resources leadership development program. Ruddy most recently served as Vice President, Communications and Corporate Citizenship and will now also oversee the company's marketing and government relations functions. Ruddy joined the company in 2014 as head of employee communications and engagement. Previously, she held communications leadership roles at Bank of America, Delhaize Group and Wachovia Corp.

06:32 EST Missfresh enters agreements with 20 regional supermarket chains in China - Missfresh has inked agreements with more than 20 regional supermarket chains to equip more than 150 stores in 19 cities in China with the company's suite of proprietary SaaS tools and AI-driven capabilities, such as smart omnichannel marketing, smart supply chain management, and smart store-to-door delivery. Missfresh's Retail Cloud business segment officially launched in June 2021 and continues to empower a growing number of neighborhood retailers through digitalization of their services, while at the same time laying the groundwork for the rapid expansion of Retail Cloud services across the neighborhood retail industry.

06:14 EST MGM Resorts to roll out new loyalty rewards program - MGM Resorts is rolling out its reimagined loyalty rewards program, MGM Rewards, on February 1, unlocking access for both gaming and non-gaming guests to the Company's 20+ destinations across the country, offering more ways to earn and new benefits. For the first time, non-gaming customers will join their gaming counterparts and have the benefit of earning a currency - MGM Rewards Points - redeemable for complimentary food and beverage, entertainment, hotel stays and more. All members can now earn Points on nearly all expenditures at MGM Resorts destinations, integrating both non-gaming and gaming activity. In addition to MGM Rewards Points, customers playing slots also will earn Slot Dollars. MGM Resorts' five member tier levels - Sapphire, Pearl, Gold, Platinum and NOIR - remain in place.

06:08 EST Precision Drilling provides capital allocation target through 2025 - Precision Drilling provided an introduction to its capital allocation framework through 2025; 2021 debt reduction and year-end liquidity updates. Precision's debt reduction plans will continue with the goal of repaying over $400M in debt over the next four years and reaching a sustained Net Debt to Adjusted EBITDA ratio of below 1.5 times. At the end of 2025, Precision expects to have reduced debt by well over $1B since 2018. In addition to debt reduction targets through 2025, Precision plans to allocate 10%-20% of free cash flow before debt principal repayments toward the return of capital to shareholders. Precision will continue to invest in routine fleet maintenance, Alpha technologies, EverGreen solutions and contracted Super Series rig upgrades. Precision reduced total debt by $115M in 2021, exceeding the midpoint of its annual debt reduction goal of $100M-$125M. As of December 31, 2021, Precision's outstanding debt obligations included $118M in Senior Credit Facility due June 18, 2025; $348M in 7.125% senior notes due January 15, 2026; and $400M in 6.875% senior notes due June 15, 2029. In addition, Precision has approximately $25M of real estate credit facilities due in 2025 and 2026. Precision's run rate cash interest expense to start 2022 is expected to be approximately $75M. The company ended 2021 with over $530M of total liquidity including a cash balance of approximately $40M and revolver availability.

06:07 EST Kennedy Wilson JV acquires 21-acre development site in Oregon - Kennedy Wilson has entered into a joint venture with Matt Day, owner of Bend-based Hooker Creek Companies, to acquire and develop a vacant 21-acre site in the heart of Bend, Oregon. Acquired on December 31, 2021, the joint venture intends to develop the site into a master-planned community that will likely include a mix of apartments, affordable senior housing, for-sale homes, office space, a boutique hotel, and retail space. The project is envisioned to create a residential and commercial hub that will feature open space accessible to the wider community in central Bend. The site is located in the heart of Bend, immediately south of Downtown Bend, just east of the Deschutes River and adjacent to the city's renowned Old Mill District.

06:02 EST PGT Innovations appoints John Kunz as CFO - PGT Innovations appointed John Kunz as Senior VP and CFO, effective January 17. Most recently, Kunz served as the Senior VP and CFO at U.S. Concrete. He also serves on the board of directors for the Wabash National Corporation. Brad West, who has been serving as Interim CFO for PGT Innovations, will resume his role as Senior VP of Corporate Development and Treasurer.

05:30 EST Mattel announces partnership between Barbie and Balmain, to enter NFT space - Mattel announced the launch of a partnership between the Barbie brand and French luxury fashion label, Balmain. The two brands are launching a new global ready-to-wear fashion and accessories collection. The venture also marks the first time Barbie is entering the digital art world. Together, the two entities are dropping three NFTs of Barbie and Ken avatars. Styled in looks from Balmain's designs, each is accompanied by a one-of-a-kind bespoke set of Barbie-sized Balmain pieces, creating a digital and physical art collection. These Barbie x Balmain NFTs will be available exclusively through Mattel Creations, via an online auction hosted on mintNFT.

05:24 EST PureTech Health announces results from LYT-100 study - PureTech Health announced results from a randomized, double-blind crossover study in healthy older adults demonstrating that approximately 50% fewer subjects treated with PureTech's LYT-100 experienced gastrointestinal, or GI-related adverse events, or AEs,compared to subjects treated with pirfenidone. Pirfenidone is approved by the FDA for the treatment of idiopathic pulmonary fibrosis, or IPF, an orphan disease that is chronic and progressive resulting in significant morbidity and mortality. Based on these results, additional data generated from PureTech's robust LYT-100 clinical program and recent regulatory feedback, the company intends to advance LYT-100 into late-stage clinical development for the treatment of IPF, beginning with a dose-ranging study evaluating six months of treatment with LYT-100 initiating in the first half of 2022. PureTech believes the results of this study, together with a Phase 3 study, could serve as the basis for registration in the U.S. Based on a recently published observational study and independent market research, only about 26% of IPF patients are treated with the current standard of care treatments despite their proven efficacy. This suggests that a vast majority of IPF patients are not currently being treated, and further supports the significant need for new, tolerable treatment options. A previous clinical study comparing a lower dose of pirfenidone than the FDA-approved dose noted a dose-efficacy response, but whether doses higher than the marketed dose can achieve increased efficacy has not been adequately explored in patients with IPF. In the upcoming dose-ranging study, PureTech also plans to investigate LYT-100 in IPF patients at a dose with a higher total drug exposure than the currently approved dose of pirfenidone to see if higher exposure results in improved efficacy. The double-blind, randomized, crossover study evaluated the tolerability of LYT-100 550 mg TID versus pirfenidone 801 mg TID in 49 healthy older adults aged 60-79, an age group consistent with that of the IPF patient population. The dose of LYT-100 used in this study was selected based on pharmacokinetics, or PK, and modeling data from prior studies, which together suggest that 550 mg TID results in similar exposure levels achieved with 801 mg TID of pirfenidone. The study showed that 38% fewer subjects treated with LYT-100 experienced any AEs compared with those treated with pirfenidone. Additionally, approximately 50% fewer subjects experienced GI-related AEs with LYT-100 compared with pirfenidone, most notably nausea, which is the most common AE associated with pirfenidone. No serious AEs were reported in the study, and there was one AE-related discontinuation in each arm. Though not powered to show statistical significance, this study provides evidence that LYT-100 has the potential to offer an important tolerability advantage over pirfenidone and helps to inform PureTech's development plans with this therapeutic candidate in IPF. Based on the data generated to date and discussions with the FDA, PureTech plans to pursue a streamlined development program for LYT-100 in IPF, capitalizing on efficiencies of the 505 pathway. The dose-ranging study, which is anticipated to begin in the first half of 2022, will enroll approximately 250 treatment naive patients to evaluate LYT-100 efficacy relative to placebo and compare relative tolerability and efficacy for pirfenidone. The planned study will evaluate TID dosing of LYT-100 taken with meals. The TID regimen is designed to reduce the maximal drug concentration, known to correlate with GI-related AEs with pirfenidone, while maintaining the same or higher overall systemic exposure as pirfenidone. Pending clinical and regulatory feedback, the program will advance into a Phase 3 study.

05:15 EST BeiGene announces China NMPA approval for tislelizumab - BeiGene announced that the China National Medical Products Administration, or NMPA, has approved BeiGene's anti-PD-1 antibody tislelizumab as a second- or third-line treatment for patients with locally advanced or metastatic non-small cell lung cancer, or NSCLC. A supplemental biologics license application for tislelizumab in this indication was previously accepted for review by the China NMPA in March.

05:09 EST Ambarella, Seeing Machines to partner on occupant and driver monitoring solution - Seeing Machines announced a collaboration with Ambarella to bring integrated advanced driver assistance system, or ADAS, and occupant and driver monitoring system solutions to the market. As part of this collaboration, Seeing Machines will enable its embedded Driver Monitoring Engine software to provide a "back end." This e-DME back end will utilize the CVflow acceleration engine inside Ambarella's SoCs, allowing forward-facing ADAS camera designers to integrate Seeing Machines' OMS and DMS technology. This agreement marks the beginning of a strategic relationship where Ambarella and Seeing Machines intend to combine their skills, products, IP and experience in the domain of embedding AI vision algorithms to deliver driver and occupant monitoring system solutions.